

Title (en)
TREATMENT OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO VEGF

Title (de)
BEHANDLUNG VON ERKRANKUNGEN IM ZUSAMMENHANG MIT DEM VASKULÄREN ENDOTHELIALEN WACHSTUMSFAKTOR (VEGF) MITTELS HEMMUNG DES NATÜRLICHEN ANTISENSE-TRANSKRIPTS GEGEN VEGF

Title (fr)
TRAITEMENT DE MALADIES APPARENTÉES AU FACTEUR DE CROISSANCE DE L'ENDOTHÉLIUM VASCULAIRE (VEGF) PAR INHIBITION DE LA TRANSCRIPTION ANTISENS NATURELLE EN VEGF

Publication
EP 2370581 A4 20131030 (EN)

Application
EP 09831074 A 20091202

Priority
• US 2009066455 W 20091202
• US 11995708 P 20081204

Abstract (en)
[origin: WO2010065671A2] Oligonucleotide compounds modulate expression and/or function of Vascular Endothelial Growth Factor (VEGF) polynucleotides and encoded products thereof. Methods for treating diseases associated with Vascular Endothelial Growth Factor (VEGF) comprise administering one or more Oligonucleotide compounds designed to inhibit the VEGF natural antisense transcript to patients.

IPC 8 full level
C12N 15/63 (2006.01); **A61K 31/712** (2006.01); **A61P 9/00** (2006.01); **C07H 19/00** (2006.01); **C12N 15/113** (2010.01); **C12Q 1/68** (2006.01)

CPC (source: EP KR US)
A61K 31/7088 (2013.01 - EP KR US); **A61K 31/712** (2013.01 - EP KR US); **A61P 1/00** (2017.12 - EP); **A61P 1/02** (2017.12 - EP); **A61P 3/04** (2017.12 - EP); **A61P 9/00** (2017.12 - EP); **A61P 9/04** (2017.12 - EP); **A61P 9/10** (2017.12 - EP); **A61P 9/12** (2017.12 - EP); **A61P 11/06** (2017.12 - EP); **A61P 13/12** (2017.12 - EP); **A61P 15/00** (2017.12 - EP); **A61P 17/00** (2017.12 - EP); **A61P 17/02** (2017.12 - EP); **A61P 17/06** (2017.12 - EP); **A61P 19/02** (2017.12 - EP); **A61P 19/08** (2017.12 - EP); **A61P 21/02** (2017.12 - EP); **A61P 25/00** (2017.12 - EP); **A61P 25/16** (2017.12 - EP); **A61P 25/28** (2017.12 - EP); **A61P 27/02** (2017.12 - EP); **A61P 29/00** (2017.12 - EP); **A61P 31/00** (2017.12 - EP); **A61P 35/00** (2017.12 - EP); **A61P 37/06** (2017.12 - EP); **A61P 37/08** (2017.12 - EP); **A61P 43/00** (2017.12 - EP); **C12N 15/1136** (2013.01 - EP KR US); **C12Q 1/6816** (2013.01 - US); **C12Q 1/6883** (2013.01 - EP KR US); **C12Q 1/6886** (2013.01 - EP KR US); **C12N 2310/11** (2013.01 - EP KR US); **C12N 2310/113** (2013.01 - US); **C12N 2310/14** (2013.01 - US); **C12N 2310/315** (2013.01 - US); **C12Q 2600/136** (2013.01 - US); **C12Q 2600/156** (2013.01 - EP KR US)

Citation (search report)
• [A] WO 0132695 A2 20010510 - GENENTECH INC [US], et al
• [A] WO 0013703 A2 20000316 - SCIOS INC [US], et al
• See references of WO 2010065671A2

Cited by
EP3511416A1; EP3260540A1

Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

DOCDB simple family (publication)
WO 2010065671 A2 20100610; WO 2010065671 A3 20100930; CA 2746003 A1 20100610; CA 2746003 C 20200331; CN 102341498 A 20120201; CN 102341498 B 20171219; EP 2370581 A2 20111005; EP 2370581 A4 20131030; EP 2370581 B1 20160803; ES 2600781 T3 20170210; JP 2012510816 A 20120517; JP 5971948 B2 20160817; KR 101761424 B1 20170726; KR 20110091775 A 20110812; MX 2011005912 A 20110617; RU 2011127212 A 20130110; RU 2569182 C2 20151120; US 2011237650 A1 20110929; US 2015141494 A1 20150521; US 2016340678 A1 20161124; US 8927511 B2 20150106; US 9410155 B2 20160809; US 9920322 B2 20180320

DOCDB simple family (application)
US 2009066455 W 20091202; CA 2746003 A 20091202; CN 200980156394 A 20091202; EP 09831074 A 20091202; ES 09831074 T 20091202; JP 2011539663 A 20091202; KR 20117014443 A 20091202; MX 2011005912 A 20091202; RU 2011127212 A 20091202; US 200913132997 A 20091202; US 201414534349 A 20141106; US 201615229426 A 20160805